CGHS maps domestic manufacturing capacity for 153 critical drugs to shorten supply delays
In order to speed up drug procurement, CGHS has directed pharmaceutical manufacturers and authorized importers to submit regulatory and production filings for oncology, diabetes, spinal muscular atrophy therapy and bispecific antibody drugs.
The Central Government Health Scheme (CGHS) is focusing on increasing the supply of critical drugs by mapping the domestic manufacturing capacity of 153 specialized medicines, according to government officials and a document reviewed by Mint. This initiative aims to reduce supply delays and ensure beneficiaries of CGHS have better access to essential medications.
Priyanka Sharma, a journalist at Mint, reported on this development, highlighting the health ministry's efforts to boost availability of these critical drugs through identifying potential suppliers across the country.
Written by urgent.news from Live Mint's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
